Plasma desmoplakin I biomarker of vascular recurrence after ischemic stroke

Journal of Neurochemistry

Volumn 121, Issue 2, 2012, Pages 314-325

  López Farré, Antonio J ^a   Zamorano León, JoséJ ^a   Segura, Antonio ^b   Mateos Cáceres, Petra J ^a   Modrego, Javier ^a   Rodríguez Sierra, Pablo ^a   Calatrava, Laura ^a   Tamargo, Juan ^c   Macaya, Carlos ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Health Sciences Institute   (Spain)

^c SCHOOL OF MEDICINE   (Spain)

Author keywords

Ischemic stroke; Statins; Vascular recurrence

Indexed keywords

BIOLOGICAL MARKER; DESMOPLAKIN; DESMOPLAKIN I; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; BRAIN ISCHEMIA; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR DISEASE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; BLOTTING, WESTERN; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DESMOPLAKINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; PROTEOMICS; RECURRENCE; STROKE; TANDEM MASS SPECTROMETRY;

EID: 84859628223     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2012.07683.x     Document Type: Article

References (44)

1. Adams H. P., Bendicen B. H., Kappelle L. J., Biller J., Love B. B., Gordon D. L. and Marsh E. E., III (1993) Classification of subtype of acute ischemic stroke. Definition for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 24, 35-41.
2. Alonso-Orgaz S., Moreno L., Macaya C., Rico L., Mateos-Cáceres P. J., Sacristán D., Pérez-Vizcaíno F., Segura A., Tamargo J. and López-Farré A. (2006) Proteomic study of plasma from moderate hypercholesterolemic patients. J. Proteome Res. 5, 2301-2308. (Pubitemid 44330823)
3. Angst B. D., Nilles L. A. and Green K. J. (1990) Desmoplakin II expression is not restricted to stratified epithelia. J. Cell Sci. 97, 247-257. (Pubitemid 20361405)
4. Beck H. and Plate K. H. (2009) Angiogenesis after cerebral ischemic. Acta Neuropathol. 117, 481-496.
5. Bornslaeger E. A., Corcoran C. M., Stappenbeck T. S. and Green K. J. (1996) Breaking the connection: displacement of the desmosomal plaque protein desmoplakin from cell-cell interfaces disrupts anchorage of intermediate filament bundles and alters intercellular junction assembly. J. Cell Biol. 134, 985-1001. (Pubitemid 26278223)
6. Castillo J., Alvarez-Sabín J., Martínez-Vila E., Montaner J., Sobrino T. and Vivancos J. (2009) MITICO Study Investigators. Inflammation markers and prediction of post-stroke vascular disease recurrence: the MITICO study. J. Neurol. 256, 217-224.
7. Cimino M., Gelosa P., Gianella A., Nobili E., Tremoli E. and Sironi L. (2007) Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist 13, 208-213. (Pubitemid 46801757)
8. Dávalos A., Castillo J. and Martinez-Vila E. (1995) Delay in neurological attention and stroke outcome. Cerebrovascular Diseases Study Group of the Spanish Society of Neurology. Stroke 26, 2233-2237.
9. Dimmeler S., Aicher A., Vasa M., Mildner-Rihm C., Adler K., Tiemann M., Rütten H., Fichtlscherer S., Martin H. and Zeiher A. M. (2001) HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 108, 391-397. (Pubitemid 32730785)
10. El Husseini N. and Laskowitz D. T. (2010) Clinical application of blood biomarkers in cerebrovascular disease. Expert Rev. Neurother. 10, 189-203 (review).
11. Fócking M., Besselmann M. and Trapp T. (2006) Proteomics of experimental stroke in mice. Acta Neurobiol. Exp. (Wars) 66, 273-278. (Pubitemid 46114711)
12. Goldstein L. B., Amarenco P., Lamonte M., Gilbert S., Messig M., Callahan A., Hennerici M., Sillesen H., Welch K. M. and SPARCL Investigators. (2008) Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke 39, 2444-2448.
13. Gorelick P. B. (2008) Lipoprotein-associated phospholipase A2 and risk of stroke. Am. J. Cardiol. 101, 34F-40F.
14. Hankey G. J. (2003) Long-term outcome after ischaemic stroke/transient ischaemic attack [Review ]. Cerebrovasc. Dis. 16, 14-19.
15. Hillen T., Coshall C., Tilling K., Rudd A. G., McGovern R. and Wolfe C. D. (2003) South London Stroke Register. Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke 34, 1457-1463.
16. Jones J. C. and Goldman R. D. (1985) Intermediate filaments and the initiation of desmosome assembly. J. Cell Biol. 101, 506-507.
17. Jorgensen H. S., Nakayama H., Reith J., Raaschou H. O. and Olsen T. Sl. (1997) Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study. Neurology 48, 891-895.
18. Kang D. W., Lattimore S. U., Latour L. L. and Warach S. (2006) Silent ischemic lesion recurrence on magnetic resonance imaging predicts subsequent clinical vascular events. Arch. Neurol. 63, 1730-1733. (Pubitemid 44925081)
19. Kiga C., Sakurai H., Goto H., Hayashi K., Shimada Y. and Saiki I. (2008) Proteomic identification of haptoglobin as a stroke plasma biomarker in spontaneously hypertensive stroke-prone rats. Life Sci. 83, 625-631.
20. Koh P. O. (2010) Proteomic analysis of focal cerebral ischemic injury in male rats. J. Vet. Med. Sci. 72, 181-185.
21. Llevadot J., Murasawa S., Kureishi Y., Uchida S., Masuda H., Kawamoto A., Walsh K., Isner J. M. and Asahara T. (2001) HMGCoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J. Clin. Invest. 8, 399-405. (Pubitemid 32730786)
22. López-Farré A. J., Mateos-Cáceres P. J., Sacristán D., Azcona L., Bernardo E., de Prada. T. P., Alonso-Orgaz S., Fernández-Arquero M., Fernández-Ortiz A. and Macaya C. (2007) Relationship between vitamin D binding protein and aspirin resistance in coronary ischemic patients: a proteomic study. J. Proteome Res. 6, 2481-2487. (Pubitemid 47122344)
23. Mateos-Cáceres P. J., García-Méndez A., López-Farré A. et al. (2004) Proteomic analysis of plasma from patients during an acute coronary syndrome. J. Am. Coll. Cardiol. 44, 1578-1583. (Pubitemid 39369788)
24. Moroney JT, Bagiella E, Paik MC, Sacco RL and Desmond DW. (1998) Risk factors for early recurrence after ischemic stroke: the role of stroke syndrome and subtype. Stroke 29, 2118-2124. (Pubitemid 28443528)
25. Mueller H. and Franke W. W. (1983) Biochemical and immunological characterization of desmoplakins I and II, the major polypeptides of the desmosomal plaque. J. Mol. Biol. 163, 647-671. (Pubitemid 13114552)
26. Ortega A., Pérez de. Prada. M. T., Mateos-Cáceres P. J. et al. (2007) Effect of parathyroid-hormone-related protein on human platelet activation. Clin. Sci. (Lond) 113, 319-27. (Pubitemid 47572272)
27. Ottens A. K., Bustamante L., Golden E. C., Yao C., Hayes R. L., Wang K. K., Tortella F. C. and Dave J. R. (2010) Neuroproteomics: a biochemical means to discriminate the extent and modality of brain injury. J. Neurotrauma 27, 1837-52.
28. Papagerakis S., Shabana A., Pollock B. H., Papagerakis P., Depondt J. and Berdal A. (2009) Altered desmoplakin expression at transcriptional and protein levels provides prognostic information in human oropharyngeal cancer. Hum. Pathol. 40, 1320-1329.
29. Sacco R. L., Foulkes M. A., Mohr J. P., Wolf P. A., Hier D. B. and Price T. R. I. (1989) Determinants of early recurrence of cerebral infarction. The Stroke Data Bank. Stroke 20, 983-989. (Pubitemid 19204008)
30. Sacristán D., Marques M., Zamorano-León J. J. et al. (2008) Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patients. Proteomics Clin. Appl. 2, 1300-1312.
31. Schmelz M. and Franke W. W. (1993) Complexus adhaerentes, a new group of desmoplakin-containing junctions in endothelial cells: the syndesmos connecting retothelial cells of lymph nodes. Eur. J. Cell Biol. 61, 274-289. (Pubitemid 23307540)
32. Selvarajah J. R., Smith C. J., Hulme S. et al. (2011) Does inflammation predispose to recurrent vascular events after recent transient ischaemic attack and minor stroke? The North West of England transient ischaemic attack and minor stroke (NORTHSTAR) study. Int. J. Stroke 6, 187-194.
33. Silva J., López-Farré A. J., Mateos-Cáceres P. J., González A., Maroto L., Macaya C. and Rodríguez E. (2008) Proteomic pattern of plasma in off-pump coronary artery bypass surgery. Clin. Chem. Lab. Med. 46, 1074-1084.
34. Stokes D. L. (2007) Desmosomes from a structural perspective [Review]. Curr. Opin. Cell Biol. 19, 565-571.
35. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. (2006) High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 355, 549-559.
36. Uzumcu A., Norgett E. E., Dindar A. et al. (2006) Loss of desmoplakin isoform I causes early onset cardiomyopathy and heart failure in a Naxos-like syndrome. J. Med. Genet. 43, 1-8.
37. Whiteley W., Jackson C., Lewis S., Lowe G., Rumley A., Sandercock P., Wardlaw J., Dennis M. and Sudlow C. (2009) Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med. 6, e1000145.
38. Wilson J. T., Hareendran A., Hendry A., Potter J., Bone I. and Muir K. Wl. (2005) Reliability of the modified Rankin Scale across multiple raters: benefits of a structured interview. Stroke 36, 777-781.
39. Woodward M., Lowe G. D., Campbell D. J. et al. (2005) Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 36, 2143-2147. (Pubitemid 41429235)
40. Xi L., Junjian Z., Yumin L., Yunwen L. and Hongbin W. (2009) Serum biomarkers of vascular cognitive impairment evaluated by bead-based proteomic technology. Neurosci. Lett. 463, 6-11.
41. Yang Z., Bowles N. E., Scherer S. E. et al. (2006) Desmosomal dysfunction due to mutations in desmoplakin causes arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ. Res. 99, 646-655. (Pubitemid 44401456)
42. Zamorano-León J. J., Modrego J., Mateos-Cáceres P. J., Macaya C., Martín-Fernández B., Miana M., de las Heras. N., Cachofeiro V., Lahera V. and López-Farré A. J. (2010) A proteomic approach to determine changes in proteins involved in the myocardial metabolism in left ventricles of spontaneously hypertensive rats. Cell Physiol. Biochem. 25, 347-358.
43. Zhang X., Guo T., Wang H., He W., Mei H., Hong M., Yu J., Hu Y. and Song S. (2008) Potential biomarkers of acute cerebral infarction detected by SELDI-TOF-MS. Am. J. Clin. Pathol. 130, 299-304.
44. Zhou X., Stuart A., Dettin L. E., Rodriguez G., Hoel B. and Gallicano G. I. (2004) Desmoplakin is required for microvascular tube formation in culture. J. Cell Sci. 117, 3129-3140. (Pubitemid 39139900)